Avanir Restructures After Ending Deals With Novartis, AstraZeneca
Plan to reduce operating expenses by $20 million will include some headcount reductions, CEO Katkin tells “The Pink Sheet” DAILY
Plan to reduce operating expenses by $20 million will include some headcount reductions, CEO Katkin tells “The Pink Sheet” DAILY